Invion Clears Debt with AU$0.8 million Convertible Note Raise

Invion Limited (ASX: IVX) has successfully raised approximately AU$782,254 through the issuance of unsecured, non-interest-bearing Convertible Notes. The funds will be used to repay its remaining obligations to Lind Global Fund II LP and support general working capital. The raise was led by Summit Biotech Fund and a specialist microcap fund, with additional support from sophisticated investors. The Convertible Notes will automatically convert to equity by 28 February 2026 or earlier if a new Photosoft™ licensing agreement with RMW Cho Group Limited becomes unconditional. Conversion pricing is capped at AU$0.11, with a floor of AU$0.07 or 80% of the 15-day VWAP. Invion will pay Blue Ocean a 6% fee and issue equity options subject to shareholder approval. This move strengthens Invion’s capital structure as it pursues global licensing opportunities for its Photosoft™ technology in cancer and infectious disease treatment.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com